|
Regeneron isn't the Pentagon, but the company is fighting some serious enemies. Regeneron Pharmaceuticals develops protein-based drugs used to battle a variety of diseases and conditions, including cancer, inflammatory ailments, and eye diseases. The biotechnology company's ARCALYST treatment for rare inflammatory diseases, including Muckle-Wells Syndrome, was approved by the FDA in 2008. Regeneron is also collaborating with Sanofi-Aventis to develop candidate VEGF Trap as a possible treatment for tumors, and it is developing VEGF Trap Eye formulation (VEGF Trap-Eye) with Bayer Healthcare for treatment of eye diseases using intraocular delivery.
|
| | | Contact Information | |
Address: |
777 Old Saw Mill River Rd.
Tarrytown, NY 10591-6707
| | Phone: | 914-345-7400 | | Fax: | 914-347-2113 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 238.50 M | | Revenue Growth (1 yr): | 90.70% | | Employees (2008): | 919 | | Employee Growth (1 yr): | 34.80% |
|
|
Key People
| | • |
Chairman:
P. Roy Vagelos
| | • |
President, CEO, and Director:
Leonard S. Schleifer
| | • |
SVP Finance and Administration, CFO, Assistant Secretary, an:
Murray A. Goldberg
|
|
|
